• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.CS-0777的发现：一种强效、选择性且口服活性的S1P1激动剂。
ACS Med Chem Lett. 2011 Mar 2;2(5):368-72. doi: 10.1021/ml100301k. eCollection 2011 May 12.
2
Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.CS-2100 的合成与评价，一种强效、口服活性且 S1P(3) 选择性保留的 S1P(1) 激动剂。
Eur J Med Chem. 2012 May;51:92-8. doi: 10.1016/j.ejmech.2012.02.022. Epub 2012 Feb 25.
3
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.发现临床候选药物GSK1842799作为一种用于治疗多发性硬化症的选择性S1P1受体激动剂（前药）。
ACS Med Chem Lett. 2013 Aug 27;4(10):942-7. doi: 10.1021/ml400194r. eCollection 2013 Oct 10.
4
Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis.开发一种选择性 S1P1 受体激动剂 Syl930，作为自身免疫性脑炎的潜在治疗药物。
Biochem Pharmacol. 2014 Jul 1;90(1):50-61. doi: 10.1016/j.bcp.2014.04.010. Epub 2014 Apr 26.
5
Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS.苯并呋喃衍生物作为强效、口服活性的S1P1受体激动剂：一种用于多发性硬化症的临床前先导分子。
ACS Med Chem Lett. 2010 Nov 9;2(2):97-101. doi: 10.1021/ml100227q. eCollection 2011 Feb 10.
6
Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5.AMG 369的发现，一种噻唑并[5,4-b]吡啶类S1P1和S1P5激动剂。
ACS Med Chem Lett. 2010 Dec 29;2(2):107-12. doi: 10.1021/ml100306h. eCollection 2011 Feb 10.
7
Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.鞘氨醇 1-磷酸受体 1 作为治疗多发性硬化症的有用靶点。
Pharmaceuticals (Basel). 2012 May 18;5(5):514-28. doi: 10.3390/ph5050514.
8
Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1).一种强效的、对1-磷酸鞘氨醇受体3（S1P3）有保留作用的1-磷酸鞘氨醇受体1（S1P1）苯并噻唑激动剂的发现。
ACS Med Chem Lett. 2010 Nov 9;2(2):102-6. doi: 10.1021/ml100228m. eCollection 2011 Feb 10.
9
ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.ASP4058是一种新型的1-磷酸鞘氨醇受体1和5激动剂，可改善啮齿动物实验性自身免疫性脑脊髓炎，且安全性良好。
PLoS One. 2014 Oct 27;9(10):e110819. doi: 10.1371/journal.pone.0110819. eCollection 2014.
10
Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor.鞘氨醇-1-磷酸1（S1P1）受体的高选择性强效激动剂。
Bioorg Med Chem Lett. 2006 Jul 15;16(14):3684-7. doi: 10.1016/j.bmcl.2006.04.064. Epub 2006 May 6.

引用本文的文献

1
Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis.多发性硬化症（MS）疾病修饰疗法（DMT）的知识图谱：一项文献计量学分析。
Heliyon. 2024 May 31;10(11):e31744. doi: 10.1016/j.heliyon.2024.e31744. eCollection 2024 Jun 15.
2
The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases.鞘氨醇-1-磷酸受体小分子调节剂治疗神经退行性疾病的研究现状。
Curr Top Med Chem. 2024;24(28):2431-2446. doi: 10.2174/0115680266288509240422112839.
3
The role of sphingosine-1-phosphate in the development and progression of Parkinson's disease.鞘氨醇-1-磷酸在帕金森病发生发展中的作用
Front Cell Neurosci. 2023 Dec 21;17:1288437. doi: 10.3389/fncel.2023.1288437. eCollection 2023.
4
Design and synthesis of some novel triazine-tyrosine hybrids as potential agents for the treatment of multiple sclerosis.一些新型三嗪 - 酪氨酸杂化物的设计与合成，作为治疗多发性硬化症的潜在药物。
Res Pharm Sci. 2022 Sep 8;17(5):482-492. doi: 10.4103/1735-5362.355208. eCollection 2022 Oct.
5
Asymmetric amination of α,α-dialkyl substituted aldehydes catalyzed by a simple chiral primary amino acid and its application to the preparation of a S1P agonist.由一种简单的手性伯氨基酸催化的α,α-二烷基取代醛的不对称胺化反应及其在S1P激动剂制备中的应用。
RSC Adv. 2019 Oct 18;9(57):33497-33505. doi: 10.1039/c9ra06210f. eCollection 2019 Oct 15.
6
Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation.鞘氨醇-1-磷酸受体调节剂和少突胶质细胞：超越免疫调节。
Int J Mol Sci. 2020 Oct 13;21(20):7537. doi: 10.3390/ijms21207537.
7
Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.靶向 SphK-S1P-SIPR 通路作为 COVID-19 的一种潜在治疗方法。
Int J Mol Sci. 2020 Sep 29;21(19):7189. doi: 10.3390/ijms21197189.
8
Positron Emission Tomography in the Inflamed Cerebellum: Addressing Novel Targets among G Protein-Coupled Receptors and Immune Receptors.炎症性小脑的正电子发射断层扫描：探寻G蛋白偶联受体和免疫受体中的新靶点
Pharmaceutics. 2020 Sep 28;12(10):925. doi: 10.3390/pharmaceutics12100925.
9
A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models.一种新型S1P1调节剂IMMH002在多种动物模型中改善银屑病。
Acta Pharm Sin B. 2020 Feb;10(2):276-288. doi: 10.1016/j.apsb.2019.11.006. Epub 2019 Nov 14.
10
S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.S1PR1 作为癌症治疗中一种新的有前途的治疗靶点。
Mol Diagn Ther. 2019 Aug;23(4):467-487. doi: 10.1007/s40291-019-00401-5.

本文引用的文献

1
Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.选择性鞘氨醇 1-磷酸受体 1 调节剂对周围 T 和 B 淋巴细胞的药理学调节。
J Clin Pharmacol. 2012 Jul;52(7):996-1006. doi: 10.1177/0091270011408728. Epub 2011 May 12.
2
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.口服芬戈莫德或肌肉注射干扰素治疗复发型多发性硬化。
N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
3
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.一项口服芬戈莫德治疗复发性多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
4
The alliance of sphingosine-1-phosphate and its receptors in immunity.鞘氨醇-1-磷酸与其受体在免疫中的联合作用。
Nat Rev Immunol. 2008 Oct;8(10):753-63. doi: 10.1038/nri2400.
5
Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.鞘氨醇-1-磷酸及免疫调节剂FTY720磷酸化形式的产生与释放。
Biochim Biophys Acta. 2008 Sep;1781(9):496-502. doi: 10.1016/j.bbalip.2008.05.003. Epub 2008 Jun 13.
6
Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.健康与疾病中的1-磷酸鞘氨醇受体：基因敲除研究及反向药理学的机制见解
Pharmacol Ther. 2007 Jul;115(1):84-105. doi: 10.1016/j.pharmthera.2007.04.006. Epub 2007 May 22.
7
Oral fingolimod (FTY720) for relapsing multiple sclerosis.口服芬戈莫德（FTY720）用于复发型多发性硬化症。
N Engl J Med. 2006 Sep 14;355(11):1124-40. doi: 10.1056/NEJMoa052643.
8
FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.新型免疫调节剂FTY720通过对1-磷酸鞘氨醇受体的激动活性，抑制淋巴细胞从次级淋巴组织和胸腺中逸出。
Pharmacol Ther. 2005 Dec;108(3):308-19. doi: 10.1016/j.pharmthera.2005.05.002. Epub 2005 Jun 13.
9
Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs.趋化因子、1-磷酸鞘氨醇与次级淋巴器官中的细胞迁移
Annu Rev Immunol. 2005;23:127-59. doi: 10.1146/annurev.immunol.23.021704.115628.
10
Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate.免疫抑制性磷酸化FTY720对映体异构体的不对称合成及生物学评价
Bioorg Med Chem. 2005 Jan 17;13(2):425-32. doi: 10.1016/j.bmc.2004.10.008.

CS-0777的发现：一种强效、选择性且口服活性的S1P1激动剂。

Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.

作者信息

Nishi Takahide, Miyazaki Shojiro, Takemoto Toshiyasu, Suzuki Keisuke, Iio Yukiko, Nakajima Katsuyoshi, Ohnuki Takashi, Kawase Yumi, Nara Futoshi, Inaba Shinichi, Izumi Takashi, Yuita Hiroshi, Oshima Keiko, Doi Hiromi, Inoue Ryotaku, Tomisato Wataru, Kagari Takashi, Shimozato Takaichi

机构信息

Lead Discovery & Optimization Research Laboratories I, Cardiovascular-Metabolics Research Laboratories, and Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd. , 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.

Oncology Research Laboratories and Frontier Research Laboratories, Daiichi Sankyo Co., Ltd. , 1-16-13 Kitakasai, Edogawa-ku, Tokyo, 134-8630, Japan.

出版信息

ACS Med Chem Lett. 2011 Mar 2;2(5):368-72. doi: 10.1021/ml100301k. eCollection 2011 May 12.

DOI:10.1021/ml100301k
PMID:24900318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4017972/
Abstract

CS-0777 (3) is phosphorylated in vivo, and the phosphate of CS-0777 (CS-0777-P) (4) acts as a selective S1P receptor-1 (S1P1) modulator. We report herein the synthesis of CS-0777 and CS-0777-P, pharmacological effects such as S1P1 and S1P3 agonist activity in vitro, peripheral blood lymphocyte lowering effects and the suppressive effect on experimental autoimmune encephalomyelitis (EAE), and also the pharmacokinetics in rats. CS-0777-P had ∼320-fold greater agonist activity for human S1P1 (EC50; 1.1 nM) relative to S1P3 (EC50; 350 nM). Following administration of single oral doses of 0.1 and 1 mg/kg of CS-0777 in rats, lymphocyte counts decreased significantly, with a nadir at 12 h postdose and recovery to vehicle control levels by 5 days postdose. In the EAE model compared to the vehicle-treated group, significant decreases in the cumulative EAE scores were observed for the 0.1 and 1 mg/kg CS-0777 groups in rats. CS-0777 is currently in clinical trials for the treatment of multiple sclerosis (MS).

摘要

CS - 0777 (3)在体内被磷酸化，CS - 0777的磷酸盐（CS - 0777 - P）（4）作为一种选择性1 -磷酸鞘氨醇受体-1（S1P1）调节剂。我们在此报告CS - 0777和CS - 0777 - P的合成、体外诸如S1P1和S1P3激动剂活性等药理作用、外周血淋巴细胞降低作用以及对实验性自身免疫性脑脊髓炎（EAE）的抑制作用，还有在大鼠体内的药代动力学。相对于S1P3（半数有效浓度EC50；350 nM），CS - 0777 - P对人S1P1（EC50；1.1 nM）的激动剂活性高约320倍。在大鼠中单次口服给予0.1和1 mg/kg的CS - 0777后，淋巴细胞计数显著下降，给药后12小时达到最低点，给药后5天恢复到溶剂对照组水平。在EAE模型中，与溶剂处理组相比，大鼠中0.1和1 mg/kg CS - 0777组的累积EAE评分显著降低。CS - 0777目前正在进行治疗多发性硬化症（MS）的临床试验。